As the winter comes and the Beijing 2022 Winter Olympics approaches, China is accelerating the inoculation of booster shots for key groups, with at least nine provinces and regions having started the campaign to further consolidate the nation's epidemic prevention and control achievements, and to improve the protection...More

A third shot of Sinovac’s COVID-19 vaccine given six months or more after the second shot would result in a remarkable increase in antibody levels, a new study has found, and a two-dose schedule appears to generate good immune memory. The results of the study were published on...More

China's Sinovac COVID-19 vaccine has been approved for emergency use among population aged between 3 and 17 years old, after phase-II clinic trial data suggests it is at least 98.9 percent effective in producing antibodies, a higher efficacy than in population over 18 years old. The experiment included...More

Chinese COVID-19 vaccine producers Sinopharm and Sinovac reached advance purchase agreements with the Global Alliance for Vaccines and Immunization (GAVI) to provide as many as 550 million doses of China-made vaccines for the world through the COVAX Facility, a move that would largely help the world tackle the...More

The world's first trial results on minors aged 3-17 showed China's inactivated COVID-19 vaccine produced by Sinovac had good safety, tolerability, and immunogenicity in youths aged 3-17 years, the Global Times learnt from Sinovac on Tuesday. Observers believe the results will inspire the ongoing trial of other COVID-19...More

China's Sinovac COVID-19 vaccine has 50.7 percent efficacy and has proved to be effective against the variants known as P1 and P2 that are prevalent in Brazil, latest data showed. Moreover, the Sinovac vaccine's efficacy rate can climb to 62.3 percent with an interval of more than 21...More